Felix Beuschlein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1353718/publications.pdf

Version: 2024-02-01

352 papers 21,636 citations

7551 77 h-index 129 g-index

364 all docs

364 docs citations

times ranked

364

14508 citing authors

#	Article	IF	CITATIONS
1	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine, 2012, 366, 2189-2197.	13.9	692
2	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer, 2009, 115, 243-250.	2.0	597
3	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	5.5	595
4	Evidence for two types of brown adipose tissue in humans. Nature Medicine, 2013, 19, 631-634.	15.2	563
5	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	9.4	560
6	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
7	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	7.7	482
8	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics, 2013, 45, 440-444.	9.4	460
9	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nature Genetics, 2015, 47, 31-38.	9.4	450
10	Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome. New England Journal of Medicine, 2014, 370, 1019-1028.	13.9	355
11	High Incidence of Adrenal Crisis in Educated Patients With Chronic Adrenal Insufficiency: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 407-416.	1.8	308
12	<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	3.2	277
13	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	1.8	274
14	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	1.3	248
15	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	1.3	246
16	Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Conn's Registry. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1125-1130.	1.8	237
17	Observational Study Mortality in Treated Primary Aldosteronism. Hypertension, 2012, 60, 618-624.	1.3	235
18	Adrenal Venous Sampling. Hypertension, 2011, 57, 990-995.	1.3	208

#	Article	IF	CITATIONS
19	High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E161-E171.	1.8	196
20	Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology, 2015, 26, 2119-2125.	0.6	196
21	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2, .	2.3	187
22	<i>KCNJ5</i> Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. Hypertension, 2012, 59, 235-240.	1.3	176
23	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	2.9	176
24	Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. European Journal of Endocrinology, 2009, 161, 355-361.	1.9	174
25	Risk Factors Associated with a Low Glomerular Filtration Rate in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 869-875.	1.8	166
26	Outcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3939-3948.	1.8	163
27	The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E997-E1004.	1.8	163
28	COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes and Endocrinology,the, 2021, 9, 786-798.	5.5	155
29	High Prevalence of Reduced Fecundity in Men with Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1665-1670.	1.8	151
30	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. Hypertension, 2014, 63, 188-195.	1.3	151
31	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension \hat{a} —. Journal of Hypertension, 2020, 38, 1919-1928.	0.3	151
32	Improved Survival in Patients with Stage II Adrenocortical Carcinoma Followed Up Prospectively by Specialized Centers. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4925-4932.	1.8	150
33	Automated Chemiluminescence-Immunoassay for Aldosterone during Dynamic Testing: Comparison to Radioimmunoassays with and without Extraction Steps. Clinical Chemistry, 2006, 52, 1749-1755.	1.5	136
34	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 181-191.	1.8	132
35	<i>ARMC5</i> Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E926-E935.	1.8	132
36	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 161-171.	1.8	131

#	Article	IF	Citations
37	The ACE-2 in COVID-19: Foe or Friend?. Hormone and Metabolic Research, 2020, 52, 257-263.	0.7	130
38	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	5.5	129
39	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. Hypertension, 2016, 67, 139-145.	1.3	127
40	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	1.8	127
41	Personalized Management of Pheochromocytoma and Paraganglioma. Endocrine Reviews, 2022, 43, 199-239.	8.9	127
42	Mass Spectrometry–Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. Clinical Chemistry, 2016, 62, 514-524.	1.5	123
43	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 2018, 64, 1646-1656.	1.5	121
44	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1122-1132.	1.8	120
45	Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. European Journal of Endocrinology, 2015, 173, 665-675.	1.9	115
46	Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. European Journal of Endocrinology, 2012, 167, 35-42.	1.9	111
47	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911.	1.8	111
48	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1686-1695.	1.8	105
49	Thyroid Hormone Replacement for Central Hypothyroidism: A Randomized Controlled Trial Comparing Two Doses of Thyroxine (T4) with a Combination of T4 and Triiodothyronine. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4115-4122.	1.8	104
50	Subclinical hypercortisolism: a state, a syndrome, or a disease? European Journal of Endocrinology, 2015, 173, M61-M71.	1.9	104
51	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2367-2374.	1.8	103
52	Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 147-155.	0.8	99
53	Adrenal Function After Adrenalectomy for Subclinical Hypercortisolism and Cushing's Syndrome: A Systematic Review of the Literature. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2637-2645.	1.8	99
54	Biochemical diagnosis of phaeochromocytoma using plasmaâ€free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clinical Endocrinology, 2014, 80, 478-486.	1.2	96

#	Article	IF	CITATIONS
55	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 312-318.	1.8	96
56	Age Below 40 or a Recently Proposed Clinical Prediction Score Cannot Bypass Adrenal Venous Sampling in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1035-E1039.	1.8	95
57	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	1.3	94
58	Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. European Journal of Endocrinology, 2011, 165, 301-306.	1.9	93
59	Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. European Journal of Endocrinology, 2012, 167, 7-15.	1.9	92
60	Novel Somatic Mutations in the Catalytic Subunit of the Protein Kinase A as a Cause of Adrenal Cushing's Syndrome: A European Multicentric Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2093-E2100.	1.8	92
61	Adrenocortical carcinoma â€" towards genomics guided clinical care. Nature Reviews Endocrinology, 2019, 15, 548-560.	4.3	92
62	Is Primary Aldosteronism Associated with Diabetes Mellitus? Results of the German Conn's Registry. Hormone and Metabolic Research, 2010, 42, 435-439.	0.7	91
63	Clonal composition of human adrenocortical neoplasms. Cancer Research, 1994, 54, 4927-32.	0.4	91
64	ACTH-receptor expression, regulation and role in adrenocortial tumor formation. European Journal of Endocrinology, 2001, 144, 199-206.	1.9	90
65	Deletion of the Adrenocorticotropin Receptor Gene in Human Adrenocortical Tumors: Implications for Tumorigenesis1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3054-3058.	1.8	89
66	[123I]lodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2358-2365.	1.8	88
67	Steroidogenic Factor-1 Is Essential for Compensatory Adrenal Growth Following Unilateral Adrenalectomy. Endocrinology, 2002, 143, 3122-3135.	1.4	84
68	Life-threatening events in patients with pheochromocytoma. European Journal of Endocrinology, 2015, 173, 757-764.	1.9	84
69	Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. European Journal of Endocrinology, 2014, 171, 209-215.	1.9	83
70	Ectopic pro-opiomelanocortin syndrome. Endocrinology and Metabolism Clinics of North America, 2002, 31, 191-234.	1.2	82
71	Growth analysis of the mouse adrenal gland from weaning to adulthood: time- and gender-dependent alterations of cell size and number in the cortical compartment. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E139-E146.	1.8	82
72	Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. Clinica Chimica Acta, 2013, 418, 50-58.	0.5	82

#	Article	IF	CITATIONS
73	Neuroendocrine Tumor Recurrence: Diagnosis with < sup > 68 < /sup > Ga-DOTATATE PET/CT. Radiology, 2014, 270, 517-525.	3.6	82
74	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2017, 177, 103-113.	1.9	82
75	Adrenal 20α-Hydroxysteroid Dehydrogenase in the Mouse Catabolizes Progesterone and 11-Deoxycorticosterone and Is Restricted to the X-Zone. Endocrinology, 2007, 148, 976-988.	1.4	80
76	Total Adrenal Volume But Not Testicular Adrenal Rest Tumor Volume Is Associated with Hormonal Control in Patients with 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2065-2072.	1.8	80
77	Aldosterone Excess Impairs First Phase Insulin Secretion in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2513-2520.	1.8	80
78	Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes and Endocrinology,the, 2022, 10, 221-230.	5.5	78
79	Acromegaly Caused by Secretion of Growth Hormone by a Non-Hodgkin's Lymphoma. New England Journal of Medicine, 2000, 342, 1871-1876.	13.9	77
80	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	1.3	77
81	Interaction Between Dax-1 and Steroidogenic Factor-1 in Vivo: Increased Adrenal Responsiveness to ACTH in the Absence of Dax-1. Endocrinology, 2002, 143, 665-673.	1.4	76
82	Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 43-48.	2.6	75
83	A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. European Journal of Endocrinology, 2015, 173, M23-M32.	1.9	74
84	Discerning malignancy in adrenocortical tumors: are molecular markers useful?. European Journal of Endocrinology, 2001, 145, 335-341.	1.9	73
85	High diagnostic accuracy of adrenal core biopsy: Results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients. Human Pathology, 2003, 34, 180-186.	1.1	73
86	Prolonged Zona Glomerulosa Insufficiency Causing Hyperkalemia in Primary Aldosteronism after Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3965-3973.	1.8	73
87	Activin Induces x-Zone Apoptosis That Inhibits Luteinizing Hormone-Dependent Adrenocortical Tumor Formation in Inhibin-Deficient Mice. Molecular and Cellular Biology, 2003, 23, 3951-3964.	1.1	72
88	Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3192-3202.	1.8	72
89	Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome. Clinical Chemistry, 2018, 64, 586-596.	1.5	70
90	Major Role of Cathepsin L for Producing the Peptide Hormones ACTH, β-Endorphin, and α-MSH, Illustrated by Protease Gene Knockout and Expression. Journal of Biological Chemistry, 2008, 283, 35652-35659.	1.6	69

#	Article	IF	CITATIONS
91	Testicular Adrenal Rest Tumors Develop Independently of Long-Term Disease Control: A Longitudinal Analysis of 50 Adult Men With Congenital Adrenal Hyperplasia due to Classic 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1820-E1826.	1.8	69
92	Screening for membrane hormone receptor expression in primary aldosteronism. European Journal of Endocrinology, 2009, 160, 443-451.	1.9	68
93	Peroxisome Proliferator-Activated Receptor-Î ³ Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3886-3896.	1.8	67
94	Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. Clinical Endocrinology, 1997, 46, 619-626.	1.2	65
95	Time to Recovery of Adrenal Function After Curative Surgery for Cushing's Syndrome Depends on Etiology. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1300-1308.	1.8	65
96	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538.	1.8	65
97	Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. European Journal of Endocrinology, 2004, 150, 329-337.	1.9	64
98	PKA catalytic subunit mutations in adrenocortical Cushing's adenoma impair association with the regulatory subunit. Nature Communications, 2014, 5, 5680.	5.8	63
99	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	1.2	63
100	Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: A cross-sectional study. World Journal of Biological Psychiatry, 2014, 15, 26-35.	1.3	62
101	Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites. European Journal of Endocrinology, 2006, 154, 865-873.	1.9	61
102	Quality of life is less impaired in adults with congenital adrenal hyperplasia because of 21-hydroxylase deficiency than in patients with primary adrenal insufficiency. Clinical Endocrinology, 2011, 74, 166-173.	1.2	61
103	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	1.1	60
104	Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. European Journal of Endocrinology, 2013, 168, 75-81.	1.9	58
105	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. European Journal of Endocrinology, 2019, 181, 409-420.	1.9	58
106	Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation. Oncotarget, 2016, 7, 79292-79304.	0.8	58
107	Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. European Journal of Endocrinology, 2017, 176, 737-746.	1.9	57
108	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440.	3.4	57

#	Article	IF	CITATIONS
109	An Update on Addison's Disease. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 165-175.	0.6	57
110	Pharmacology and Pathophysiology of Mutated KCNJ5 Found in Adrenal Aldosterone-Producing Adenomas. Endocrinology, 2014, 155, 1353-1362.	1.4	56
111	Cellular Pathophysiology of an Adrenal Adenoma-Associated Mutant of the Plasma Membrane Ca2+-ATPase ATP2B3. Endocrinology, 2016, 157, 2489-2499.	1.4	54
112	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	4.6	54
113	Characterization of an Adrenocorticotropin (ACTH) Receptor Promoter Polymorphism Leading to Decreased Adrenal Responsiveness to ACTH. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3131-3137.	1.8	53
114	Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Molecular Psychiatry, 2010, 15, 426-441.	4.1	53
115	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	3.2	53
116	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. JAMA Network Open, 2020, 3, e2016209.	2.8	53
117	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. Annals of Internal Medicine, 2022, 175, 325-334.	2.0	53
118	Association of plasma aldosterone with the metabolic syndrome in two German populations. European Journal of Endocrinology, 2011, 164, 751-758.	1.9	51
119	Contemporary microsurgical concept for the treatment of Cushing's disease: endocrine outcome in 83 consecutive patients. Clinical Endocrinology, 2012, 76, 560-567.	1.2	51
120	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657.	1.3	51
121	ACTH-Dependent Regulation of MicroRNA As Endogenous Modulators of Glucocorticoid Receptor Expression in the Adrenal Gland. Endocrinology, 2012, 153, 212-222.	1.4	50
122	Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clinica Chimica Acta, 2019, 490, 46-54.	0.5	50
123	Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2985-2993.	1.8	49
124	Timelines in the management of adrenal crisis – targets, limits and reality. Clinical Endocrinology, 2015, 82, 497-502.	1.2	48
125	Pre-B-Cell Transcription Factor 1 and Steroidogenic Factor 1 Synergistically Regulate Adrenocortical Growth and Steroidogenesis. Endocrinology, 2007, 148, 693-704.	1.4	47
126	Side Population Does Not Define Stem Cell-Like Cancer Cells in the Adrenocortical Carcinoma Cell Line NCI h295R. Endocrinology, 2008, 149, 1314-1322.	1.4	47

#	Article	IF	CITATIONS
127	Quality of life in patients with primary aldosteronism: Gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. Journal of Psychiatric Research, 2012, 46, 1650-1654.	1.5	47
128	Adrenal Cortical Insufficiency. Deutsches Ärzteblatt International, 2013, 110, 882-8.	0.6	47
129	Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4543-4552.	1.8	47
130	The Diagnosis and Treatment of Primary Hyperaldosteronism in Germany. Deutsches Ärzteblatt International, 2009, 106, 305-11.	0.6	47
131	Steroid 21-Hydroxylase Mutations and 21-Hydroxylase Messenger Ribonucleic Acid Expression in Human Adrenocortical Tumors1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2585-2588.	1.8	46
132	SF-1, DAX-1, AND ACD: MOLECULAR DETERMINANTS OF ADRENOCORTICAL GROWTH AND STEROIDOGENESIS. Endocrine Research, 2002, 28, 597-607.	0.6	46
133	Toward a Diagnostic Score in Cushing's Syndrome. Frontiers in Endocrinology, 2019, 10, 766.	1.5	46
134	COVID-19 targets human adrenal glands. Lancet Diabetes and Endocrinology, the, 2022, 10, 13-16.	5.5	46
135	Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e307-e318.	1.8	45
136	Silencing Mutated \hat{l}^2 -Catenin Inhibits Cell Proliferation and Stimulates Apoptosis in the Adrenocortical Cancer Cell Line H295R. PLoS ONE, 2013, 8, e55743.	1.1	45
137	Bone Morphogenetic Proteins 2 and 5 Are Down-regulated in Adrenocortical Carcinoma and Modulate Adrenal Cell Proliferation and Steroidogenesis. Cancer Research, 2009, 69, 5784-5792.	0.4	44
138	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3205.	1.8	44
139	Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany. Deutsches Ärzteblatt International, 2010, 107, 885-91.	0.6	44
140	AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4366-4370.	1.8	43
141	PRKACA Somatic Mutations Are Rare Findings in Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3010-3017.	1.8	43
142	DAX-1 Expression in Human Adrenocortical Neoplasms: Implications for Steroidogenesis. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2597-2600.	1.8	42
143	A highly sensitive immunofluorometric assay for the measurement of aldosterone in small sample volumes: validation in mouse serum. Journal of Endocrinology, 2008, 196, 215-224.	1.2	42
144	H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1376-E1380.	1.8	42

#	Article	IF	CITATIONS
145	Frequency and Clinical Correlates of Somatic Ying Yang 1 Mutations in Sporadic Insulinomas. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E776-E782.	1.8	42
146	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. Science Advances, 2021, 7, .	4.7	42
147	Steroid 21-Hydroxylase Mutations and 21-Hydroxylase Messenger Ribonucleic Acid Expression in Human Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2585-2588.	1.8	42
148	Localization and expression of adrenocorticotropic hormone receptor mRNA in normal and neoplastic human adrenal cortex. Journal of Endocrinology, 1998, 156, 415-423.	1.2	41
149	Presence of Brown Adipocytes in Retroperitoneal Fat From Patients With Benign Adrenal Tumors: Relationship With Outdoor Temperature. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4097-4104.	1.8	41
150	EJE Prize 2013: Regulation of aldosterone secretion: from physiology to disease. European Journal of Endocrinology, 2013, 168, R85-R93.	1.9	41
151	Linear and Volumetric Evaluation of the Adrenal Gland—MDCT-Based Measurements of the Adrenals. Academic Radiology, 2014, 21, 1465-1474.	1.3	41
152	Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms. Clinical Endocrinology, 2001, 54, 627-632.	1.2	37
153	Adrenal Insufficiency After Unilateral Adrenalectomy in Primary Aldosteronism: Long-Term Outcome and Clinical Impact. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5658-5664.	1.8	37
154	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor. European Journal of Endocrinology, 2018, 178, 57-63.	1.9	37
155	Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18493-18498.	3.3	36
156	Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of \hat{l}^2 -catenin in adrenocortical carcinoma. Oncogenesis, 2015, 4, e161-e161.	2.1	36
157	CBP/p300-Interacting Transactivator, with Glu/Asp-Rich C-Terminal Domain, 2, and Pre-B-Cell Leukemia Transcription Factor 1 in Human Adrenal Development and Disease. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 678-683.	1.8	35
158	A High Aldosterone to Renin Ratio Is Associated With High Serum Parathyroid Hormone Concentrations in the General Population. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 965-971.	1.8	35
159	Plasma Steroid Profiles in Subclinical Compared With Overt Adrenal Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4331-4340.	1.8	35
160	The role of regulated necrosis in endocrine diseases. Nature Reviews Endocrinology, 2021, 17, 497-510.	4.3	35
161	Gonadectomy in mice of the inbred strain CE/J induces proliferation of sub-capsular adrenal cells expressing gonadal marker genes. Journal of Endocrinology, 2006, 190, 47-57.	1.2	34
162	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3295-3307.	1.8	34

#	Article	IF	CITATIONS
163	ACTH after 15 min distinguishes between Cushing's disease and ectopic Cushing's syndrome: a proposal for a short and simple CRH test. European Journal of Endocrinology, 2015, 173, 197-204.	1.9	33
164	The SPARTACUS Trial: Controversies and Unresolved Issues. Hormone and Metabolic Research, 2017, 49, 936-942.	0.7	33
165	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	1.8	33
166	Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nature Metabolism, 2021, 3, 289-292.	5.1	33
167	HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocrine-Related Cancer, 2020, 27, 625-640.	1.6	33
168	cAMP signaling in cortisol-producing adrenal adenoma. European Journal of Endocrinology, 2015, 173, M99-M106.	1.9	32
169	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 353-363.	1.4	32
170	The Prevalence of Familial Hyperaldosteronism in Apparently Sporadic Primary Aldosteronism in Germany: a Single Center Experience. Hormone and Metabolic Research, 2012, 44, 215-220.	0.7	31
171	\hat{l}^2 -Catenin and FGFR2 regulate postnatal rosette-based adrenocortical morphogenesis. Nature Communications, 2020, $11,1680$.	5.8	31
172	Expression and spatio-temporal distribution of differentiation and proliferation markers during mouse adrenal development. Gene Expression Patterns, 2007, 7, 72-81.	0.3	30
173	Animal models of adrenocortical tumorigenesis. Molecular and Cellular Endocrinology, 2012, 351, 78-86.	1.6	30
174	Current Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2853-e2863.	1.8	30
175	Peripheral administration of the N-terminal pro-opiomelanocortin fragment 1–28 to Pomcâ-'/â-' mice reduces food intake and weight but does not affect adrenal growth or corticosterone production. Journal of Endocrinology, 2006, 190, 515-525.	1.2	29
176	Links between aldosterone excess and metabolic complications: A comprehensive review. Diabetes and Metabolism, 2020, 46, 1-7.	1.4	29
177	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e282-e289.	1.8	29
178	Persisting Muscle Dysfunction in Cushing's Syndrome Despite Biochemical Remission. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4490-e4498.	1.8	29
179	Intraoperative haemodynamic stability in patients with phaeochromocytoma? minimally invasive vs conventional open surgery. Clinical Endocrinology, 2006, 65, 352-358.	1.2	28
180	Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. International Journal of Oncology, 2013, 43, 1824-1832.	1.4	28

#	Article	IF	Citations
181	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 274-282.	1.2	28
182	Molecular adrenocortical tumourigenesis. European Journal of Clinical Investigation, 2000, 30, 63-68.	1.7	27
183	Primary Aldosteronism. Hypertension, 2019, 74, 809-816.	1.3	27
184	In situ metabolomics of aldosterone-producing adenomas. JCI Insight, 2019, 4, .	2.3	27
185	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2027-e2036.	1.8	27
186	Steroidogenic acute regulatory protein mRNA expression in adrenal tumours. European Journal of Endocrinology, 2000, 142, 294-299.	1.9	26
187	Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Annals of Clinical Biochemistry, 2014, 51, 38-46.	0.8	26
188	Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. European Journal of Endocrinology, 2015, 172, 443-450.	1.9	26
189	Cushing's syndrome: a model for sarcopenic obesity. Endocrine, 2017, 57, 481-485.	1.1	26
190	Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. European Journal of Endocrinology, 2018, 178, 605-611.	1.9	26
191	Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. Journal of Medical Genetics, 2022, 59, 287-293.	1.5	26
192	Spontaneous remission of idiopathic aldosteronism after longâ€term treatment with spironolactone: results from the German Conn's Registry. Clinical Endocrinology, 2012, 76, 473-477.	1.2	25
193	Adrenal Venous Sampling–Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1400-e1407.	1.8	25
194	ACTH 1-24 inhibits proliferation of adrenocortical tumors in vivo. European Journal of Endocrinology, 2005, 153, 435-444.	1.9	24
195	MANAGEMENT OF ENDOCRINE DISEASE: Fertility, pregnancy and lactation in women with adrenal insufficiency. European Journal of Endocrinology, 2018, 178, R45-R53.	1.9	24
196	Surviving ectopic Cushing's syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing's disease during long-term follow-up. European Journal of Endocrinology, 2018, 179, 109-116.	1.9	24
197	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	1.4	24
198	Performance of LC–MS/MS and immunoassay based 24-h urine free cortisol in the diagnosis of Cushing's syndrome. Journal of Steroid Biochemistry and Molecular Biology, 2019, 190, 193-197.	1.2	24

#	Article	IF	CITATIONS
199	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4459-e4473.	1.8	24
200	Interaction Between Dax-1 and Steroidogenic Factor-1 in Vivo: Increased Adrenal Responsiveness to ACTH in the Absence of Dax-1. , 0, .		24
201	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. European Journal of Endocrinology, 2017, 177, 227-237.	1.9	23
202	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. Cancers, 2019, 11, 809.	1.7	23
203	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. Journal of Pathology, 2020, 251, 378-387.	2.1	23
204	Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients. European Journal of Endocrinology, 2013, 169, 657-663.	1.9	22
205	Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine, 2016, 54, 198-205.	1.1	22
206	Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series. Endocrine, 2017, 58, 503-512.	1.1	22
207	Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort. Journal of Inherited Metabolic Disease, 2020, 43, 326-333.	1.7	22
208	Role of the Inhibin/Activin System and Luteinizing Hormone in Adrenocortical Tumorigenesis. Hormone and Metabolic Research, 2004, 36, 392-396.	0.7	21
209	Characterization of NCI-H295R Cells as an In Vitro Model of Hyperaldosteronism. Hormone and Metabolic Research, 2013, 45, 124-129.	0.7	21
210	Diastrophic Dysplasia Sulfate Transporter (SLC26A2) Is Expressed in the Adrenal Cortex and Regulates Aldosterone Secretion. Hypertension, 2014, 63, 1102-1109.	1.3	21
211	Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. Endocrine-Related Cancer, 2014, 21, 383-394.	1.6	21
212	Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma <i>in vitro</i> and <i>in vivo</i> lnternational Journal of Cancer, 2018, 143, 199-211.	2.3	21
213	Metabolic Alterations in Patients with Pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 129-136.	0.6	21
214	Stress-inducible-stem cells: a new view on endocrine, metabolic and mental disease?. Molecular Psychiatry, 2019, 24, 2-9.	4.1	21
215	Genetic influence of an ACTH receptor promoter polymorphism on adrenal androgen secretion. European Journal of Endocrinology, 2005, 153, 711-715.	1.9	20
216	Evaluation of a Standardized Protocol for Processing Adrenal Tumor Samples: Preparation for a European Adrenal Tumor Bank. Hormone and Metabolic Research, 2010, 42, 93-101.	0.7	20

#	Article	IF	Citations
217	A microsphere-based duplex competitive immunoassay for the simultaneous measurements of aldosterone and testosterone in small sample volumes: Validation in human and mouse plasma. Steroids, 2010, 75, 1089-1096.	0.8	20
218	Therapeutic options after surgical failure in Cushing's disease: A critical review. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101270.	2.2	20
219	The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression – Lessons from primary aldosteronism. Journal of Psychiatric Research, 2020, 130, 82-88.	1.5	20
220	The Effect of Biochemical Remission on Bone Metabolism in Cushing's Syndrome: A 2â€Year Followâ€Up Study. Journal of Bone and Mineral Research, 2020, 35, 1711-1717.	3.1	20
221	Tumor Size of Conn's Adenoma and Comorbidities. Hormone and Metabolic Research, 2009, 41, 785-788.	0.7	19
222	Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma. Journal of Endocrinology, 2012, 213, 155-161.	1.2	19
223	Association between 25-Hydroxyvitamin D Status and Components of Body Composition and Glucose Metabolism in Older Men and Women. Nutrients, 2018, 10, 1826.	1.7	19
224	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3812-3820.	1.8	19
225	Proteomic Landscape of Aldosterone-Producing Adenoma. Hypertension, 2019, 73, 469-480.	1.3	19
226	Hypokalemia and the Prevalence of Primary Aldosteronism. Hormone and Metabolic Research, 2020, 52, 347-356.	0.7	19
227	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	1.8	19
228	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. European Journal of Endocrinology, 2019, 181, 647-657.	1.9	19
229	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1181-e1192.	1.8	19
230	Short term regulation of aldosterone secretion after stimulation and suppression experiments in mice. Journal of Molecular Endocrinology, 2009, 42, 407-413.	1.1	18
231	Isoenergetic Feeding of Low Carbohydrate-High Fat Diets Does Not Increase Brown Adipose Tissue Thermogenic Capacity in Rats. PLoS ONE, 2012, 7, e38997.	1.1	18
232	KCNJ5 Mutations: Sex, Salt and Selection. Hormone and Metabolic Research, 2015, 47, 953-958.	0.7	18
233	TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors. Molecular and Cellular Endocrinology, 2016, 423, 87-95.	1.6	18
234	The impact of Connshing's syndrome - mild cortisol excess in primary aldosteronism drives diabetes risk. Journal of Hypertension, 2017, 35, 2548.	0.3	18

#	Article	IF	CITATIONS
235	Steroidogenic Factor-1 Is Essential for Compensatory Adrenal Growth Following Unilateral Adrenalectomy. , 0, .		18
236	DAX-1 Expression in Human Adrenocortical Neoplasms: Implications for Steroidogenesis. , 0, .		18
237	Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study. European Journal of Endocrinology, 2020, 183, 453-462.	1.9	18
238	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. European Journal of Cancer, 2022, 169, 32-41.	1.3	18
239	Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations. European Journal of Endocrinology, 2015, 173, 43-52.	1.9	17
240	Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma. European Journal of Endocrinology, 2015, 172, 89-95.	1.9	17
241	Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. Endocrine-Related Cancer, 2016, 23, 825-837.	1.6	17
242	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. Scientific Reports, 2017, 7, 49.	1.6	17
243	Diverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism. Hypertension, 2019, 74, 784-792.	1.3	17
244	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	1.8	17
245	Is there a role for the adrenal glands in long COVID?. Nature Reviews Endocrinology, 2022, 18, 451-452.	4.3	17
246	Steroidogenic Acute Regulatory (StAR)-Directed Immunotherapy Protects against Tumor Growth of StAR-Expressing Sp2-0 Cells in a Rodent Adrenocortical Carcinoma Model. Endocrinology, 2004, 145, 1760-1766.	1.4	16
247	Anti Insulin-Like Growth Factor I Receptor Immunoliposomes: A Single Formulation Combining Two Anticancer Treatments with Enhanced Therapeutic Efficiency. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 943-952.	1.8	16
248	Aldosterone Producing Adrenal Adenomas are Characterized by Activation of Calcium/Calmodulin-dependent Protein Kinase (CaMK) Dependent Pathways. Hormone and Metabolic Research, 2011, 43, 106-111.	0.7	16
249	Advances in adrenal tumors 2018. Endocrine-Related Cancer, 2018, 25, R405-R420.	1.6	16
250	Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients. Journal of the Endocrine Society, 2021, 5, A166-A167.	0.1	16
251	Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated ⟨i⟩in vitro⟨ i⟩and⟨i⟩in vivo⟨ i⟩â€" challenges and prospects. Oncotarget, 2015, 6, 43698-43711.	0.8	15
252	Genetics of adrenocortical tumours. Journal of Internal Medicine, 2016, 280, 540-550.	2.7	15

#	Article	IF	CITATIONS
253	The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism. Journal of Hypertension, 2016, 34, 2066-2073.	0.3	15
254	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. European Journal of Endocrinology, 2018, 178, 181-188.	1.9	15
255	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 578-584.	0.6	15
256	Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. Oncotarget, 2015, 6, 39111-39126.	0.8	15
257	Adrenocortical Tumorigenesis. Annals of the New York Academy of Sciences, 2006, 1088, 319-334.	1.8	14
258	Role of bone morphogenetic proteins in adrenal physiology and disease. Journal of Molecular Endocrinology, 2010, 44, 203-211.	1.1	14
259	Primary Adrenal Lymphoma: 3 Case Reports with Different Outcomes. Experimental and Clinical Endocrinology and Diabetes, 2011, 119, 208-213.	0.6	14
260	Xenograft models for adrenocortical carcinoma. Molecular and Cellular Endocrinology, 2016, 421, 28-33.	1.6	14
261	Expression and mutational status of USP8 in tumors causing ectopic ACTH secretion syndrome. Endocrine-Related Cancer, 2017, 24, L73-L77.	1.6	14
262	Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. Frontiers in Endocrinology, 2019, 10, 487.	1.5	14
263	Primary and Secondary Hyperparathyroidism in Patients with Primary Aldosteronism – Findings From the German Conn's Registry. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 246-254.	0.6	14
264	Altered Taste Perception for Sodium Chloride in Patients With Primary Aldosteronism. Hypertension, 2021, 77, 1332-1340.	1.3	14
265	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine, 2021, 11, 269.	1.1	14
266	Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3723-e3730.	1.8	14
267	Volumetric and densitometric evaluation of the adrenal glands in patients with primary aldosteronism. Clinical Endocrinology, 2017, 86, 325-331.	1.2	13
268	Perioperative Management of Endocrine Active Adrenal Tumors. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 137-146.	0.6	13
269	Endocrine responses during CPAP withdrawal in obstructive sleep apnoea: data from two randomised controlled trials. Thorax, 2019, 74, 1102-1105.	2.7	13
270	Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety. Journal of Psychiatric Research, 2021, 137, 376-382.	1.5	13

#	Article	IF	Citations
271	Patients with low IGF-I after curative surgery for Cushing's syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy. European Journal of Endocrinology, 2021, 184, 813-821.	1.9	13
272	Aged PROP1 Deficient Dwarf Mice Maintain ACTH Production. PLoS ONE, 2011, 6, e28355.	1.1	13
273	Identification of adrenal genes regulated in a potassium-dependent manner. Journal of Molecular Endocrinology, 2010, 45, 193-206.	1.1	12
274	Daily adjustment of glucocorticoids by patients with adrenal insufficiency. Clinical Endocrinology, 2019, 91, 256-262.	1.2	12
275	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. International Journal of Obesity, 2019, 43, 263-275.	1.6	12
276	Patients With Primary Aldosteronism Respond to Unilateral Adrenalectomy With Long-Term Reduction in Salt Intake. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e484-e493.	1.8	12
277	Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101347.	2.2	12
278	Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2021, 185, 179-191.	1.9	12
279	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-Related Cancer, 2022, 29, 285-306.	1.6	12
280	Clinical and molecular evidence for DAX-1 inhibition of steroidogenic factor-1-dependent ACTH receptor gene expression. European Journal of Endocrinology, 2005, 152, 769-776.	1.9	11
281	Gender-, strain-, and inheritance-dependent variation in aldosterone secretion in mice. Journal of Endocrinology, 2012, 215, 375-381.	1.2	11
282	IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma. Molecular and Cellular Endocrinology, 2016, 428, 82-88.	1.6	11
283	Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy. Hormone and Metabolic Research, 2017, 49, 208-213.	0.7	11
284	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. Metabolism: Clinical and Experimental, 2020, 110, 154297.	1.5	11
285	Circulating microRNA Expression in Cushing's Syndrome. Frontiers in Endocrinology, 2021, 12, 620012.	1.5	11
286	Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. Endocrine Connections, 2018, 7, 1168-1177.	0.8	11
287	The Role of the ACTH Receptor in Adrenal Tumors: Identification of a Novel Microsatellite Marker. Hormone and Metabolic Research, 2004, 36, 406-410.	0.7	10
288	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. Hypertension, 2015, 66, 248-253.	1.3	10

#	Article	IF	CITATIONS
289	PRKACA Mutations in Adrenal Adenomas: Genotype/Phenotype Correlations. Hormone and Metabolic Research, 2017, 49, 301-306.	0.7	10
290	Adrenal Incidentalomas: Presentation and Clinical Work-Up. Hormone Research in Paediatrics, 2007, 68, 191-194.	0.8	9
291	PBX1 is dispensable for neural commitment of RA-treated murine ES cells. In Vitro Cellular and Developmental Biology - Animal, 2009, 45, 252-263.	0.7	9
292	Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 547-560.	1.6	9
293	Comparative Genomics and Transcriptome Profiling in Primary Aldosteronism. International Journal of Molecular Sciences, 2018, 19, 1124.	1.8	9
294	The role of adrenal venous sampling (AVS) in primary bilateral macronodular adrenocortical hyperplasia (PBMAH): a study of 16 patients. Endocrine, 2022, 76, 434-445.	1.1	9
295	The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex – a multicenter-study of 3566 Caucasian and Asian subjects. European Journal of Endocrinology, 2022, 187, 361-372.	1.9	9
296	Regulation of Human MC2-R Gene Expression by CREB, CREM, and ICER in the Adrenocortical Cell Line Y1. Hormone and Metabolic Research, 2007, 39, 560-566.	0.7	8
297	Beyond a Disease Registry: An Integrated Virtual Environment for Adrenal Cancer Research. Journal of Grid Computing, 2016, 14, 515-532.	2.5	8
298	Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells. Cancer Letters, 2017, 406, 54-63.	3.2	8
299	BEX1 Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. Hypertension, 2021, 77, 1647-1658.	1.3	8
300	Novel molecular signatures for adrenocortical carcinoma. Nature Reviews Endocrinology, 2009, 5, 297-299.	4.3	7
301	Utilization of a Mutagenesis Screen to Generate Mouse Models of Hyperaldosteronism. Endocrinology, 2011, 152, 326-331.	1.4	7
302	Sleep quality in patients with primary aldosteronism. Hormones, 2014, 13, 57-64.	0.9	7
303	Treatment of Primary Aldosteronism With mTORC1 Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4703-4714.	1.8	7
304	Identification of glucocorticoid-related molecular signature by whole blood methylome analysis. European Journal of Endocrinology, 2022, 186, 297-308.	1.9	7
305	Decreased p44/42 Mitogen-Activated Protein Kinase Phosphorylation in Gender- or Hormone-Related But Not during Age-Related Adrenal Gland Growth in Mice. Endocrinology, 2009, 150, 1269-1277.	1.4	6
306	The tumor stem cell conceptâ€"Implications for endocrine tumors?. Molecular and Cellular Endocrinology, 2009, 300, 158-163.	1.6	6

#	Article	IF	Citations
307	Mouse models of adrenal tumorigenesis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 865-875.	2.2	6
308	Progress in Primary Aldosteronism: Translation on the Move. Hormone and Metabolic Research, 2015, 47, 933-934.	0.7	6
309	Characteristics of preoperative steroid profiles and glucose metabolism in patients with primary aldosteronism developing adrenal insufficiency after adrenalectomy. Scientific Reports, 2021, 11, 11181.	1.6	6
310	Animal Models of Primary Aldosteronism. Hormone and Metabolic Research, 2010, 42, 446-449.	0.7	5
311	Urocortin-dependent effects on adrenal morphology, growth, and expression of steroidogenic enzymes in vivo. Journal of Molecular Endocrinology, 2012, 48, 159-167.	1.1	5
312	Virilization of a Young Girl Caused by Concomitant Ectopic and Intra-Adrenal Adenomas of the Adrenal Cortex. Hormone Research in Paediatrics, 2013, 79, 318-322.	0.8	5
313	Novel genes in primary aldosteronism. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 154-158.	1.2	5
314	Adrenal and Ovarian Phenotype of a Tissue-Specific Urocortin 2–Overexpressing Mouse Model. Endocrinology, 2015, 156, 2646-2656.	1.4	5
315	Genetic characterization of a mouse line with primary aldosteronism. Journal of Molecular Endocrinology, 2017, 58, 67-78.	1.1	5
316	The Adrenal Gland: Central Relay in Health and Disease. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 81-83.	0.6	5
317	Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion. Discover Oncology, 2021, 12, 9.	0.8	5
318	Cytotoxic T-cell Response against Steroidogenic Acute Regulatory Protein using DNA Vaccination Followed by Vaccinia Virus Infection in a Mouse Adrenal Carcinoma Model. Hormone and Metabolic Research, 2004, 36, 411-414.	0.7	4
319	Mechanistic Roles of Inhibin as a Tumor Suppressor in the Adrenal Cortex. Endocrine Research, 2004, 30, 585-586.	0.6	4
320	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1262-E1269.	1.8	4
321	Somatic PRKACA Mutations: Association With Transition From Pituitary-Dependent to Adrenal-Dependent Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5651-5657.	1.8	4
322	Effects of chronically high levels of aldosterone on different cognitive dimensions: an investigation in patients with primary aldosteronism. Endocrine Connections, 2019, 8, 407-415.	0.8	4
323	Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma. Endocrinology, 2022, 163, .	1.4	4
324	Signs, symptoms and biochemistry in recurrent Cushing disease: a prospective pilot study. Endocrine, 2021, 73, 762-766.	1.1	3

#	Article	IF	CITATIONS
325	Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma. Endocrine, 2022, 75, 254-265.	1.1	3
326	Clinical Impact of Recent Advances in the Biology of Adrenocortical Cancer., 2003, 13, 470-478.		2
327	Connshing syndrome–Âmyth or reality?. Annales D'Endocrinologie, 2018, 79, 123-124.	0.6	2
328	Sleep-EEG in patients with primary aldosteronism in comparison to healthy controls and patients with depression. Journal of Psychiatric Research, 2019, 112, 52-60.	1.5	2
329	Circular RNA-based biomarkers in blood of patients with Fabry disease and related phenotypes. Journal of Medical Genetics, 2021, , jmedgenet-2020-107086.	1.5	2
330	Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma. Journal of the Endocrine Society, 2021, 5, A70-A70.	0.1	2
331	Somatic RET mutation in a patient with pigmented adrenal pheochromocytoma. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 150117.	0.2	2
332	Endocrine disorders in patients with Fabry disease: insights from a reference centre prospective study. Endocrine, 2022, 75, 728-739.	1.1	2
333	Incidence of Primary Aldosteronism in Patients with Hypokalemia (IPAHK+): Study Design and Baseline Characteristics. Hormone and Metabolic Research, 2021, 53, 787-793.	0.7	2
334	The side population phenomenon enriches for designated adrenocortical progenitor cells in mice. Journal of Endocrinology, 2012, 215, 383-391.	1.2	1
335	Animal Models of Adrenal Genetic Disorders. , 2014, , 323-329.		1
336	Predicitve Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. Hormone and Metabolic Research, 2021, 53, 24-31.	0.7	1
337	OR34-02 Somatic Transmembrane Domain Mutations of a Cell Adhesion Molecule, CADM1, Cause Primary Aldosteronism by Preventing Gap Junction Communication Between Adrenocortical Cells. Journal of the Endocrine Society, 2020, 4, .	0.1	1
338	Progress in Primary Aldosteronism 2. Hormone and Metabolic Research, 2012, 44, 155-156.	0.7	0
339	[OP.3A.06] LONG TERM FOLLOW-UP IN PATIENTS OPERATED ON A PHEOCHROMOCYTOMA OR A PARAGANGLIOMA. Journal of Hypertension, 2016, 34, e28.	0.3	0
340	Dopamine agonist-responsive Cushing's disease. BMJ Case Reports, 2019, 12, bcr-2018-228045.	0.2	0
341	Response to Letter to the Editor: "CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3842-e3843.	1.8	0
342	Calcineurin-NFATc4 Pathway Is Activated Upon K+-stimulation of Adrenal Aldosterone Production. Journal of the Endocrine Society, 2021, 5, A805-A806.	0.1	0

#	Article	IF	CITATIONS
343	Aldosterone Insufficiency Contributes to Calcineurin Inhibitorâ€induced Hyperkalemia. FASEB Journal, 2021, 35, .	0.2	0
344	Mouse Models of Adrenal Tumorigenesis. , 2009, , 325-340.		0
345	Diagnosis and Treatment of Primary Aldosteronism in 2017: Did We Achieve Our Goals?. Hormone and Metabolic Research, 2017, 49, 905-907.	0.7	0
346	OR29-2 Mild Autonomous Cortisol Excess (MACE) in Adrenal Incidentalomas - Metabolic Risk Profile and Urinary Steroid Metabolome Analysis in 1208 Prospectively Recruited Patients. Journal of the Endocrine Society, 2019, 3, .	0.1	0
347	SUN-381 Somatic PRKACA Mutations In Patients With Transition From Pituitary-dependent To Adrenal-dependent Cushing'S Syndrome. Journal of the Endocrine Society, 2019, 3, .	0.1	0
348	MON-380 Tinnitus with Unexpected Spanish Roots: Head and Neck Paragangliomas Caused by SDHAF2 Mutation. Journal of the Endocrine Society, 2019, 3 , .	0.1	0
349	SAT-LB23 Paraneoplastic Hypercalcemia in a PTH Producing Adrenocortical Carcinoma - a Rare and Deadly Condition. Journal of the Endocrine Society, 2020, 4, .	0.1	0
350	OR34-04 Efficiency of Adrenal Venous Sampling in the Treatment Choice of Primary Aldosteronism (AVSTAT Study). Journal of the Endocrine Society, 2020, 4, .	0.1	0
351	MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. Journal of the Endocrine Society, 2020, 4, .	0.1	0
352	COVID-19 in Fabry disease: a reference center prospective study. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	0